Latest Adalimumab Stories
INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment
PRINCETON, N.J., April 14, 2015 /PRNewswire/ -- Soligenix, Inc.
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides
DALLAS, March 18, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" market research report provides
- 22 abstracts further evaluate the safety, efficacy of HUMIRA in psoriatic arthritis and moderate to severe chronic plaque psoriasis and investigational use of HUMIRA for the treatment of moderate
DALLAS, March 13, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Hidradenitis Suppurativa - Pipeline Review, H1 2015" therapeutic market research report provides an overview
CRANBURY, N.J., Feb.
Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Feb.
RnRMarketResearch.com adds "Hidradenitis Suppurativa - Pipeline Review, H2 2014" to its store.
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
- Emitting flashes of light; glittering.